Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Alexanian

Showing results (41-50 of 196) with videos related to

Pageof 20
Sort By:
Seminars in Hematology|January 1, 1995
Management of multiple myelomaR Alexanian, M A Dimopoulos
Journal of Tissue Engineering and Regenerative Medicine|June 8, 2012
The neural plasticity of early-passage human bone marrow-derived mesenchymal stem cells and their modulation with chromatin-modifying agentsZhiying Zhang, Arshak R Alexanian
Journal of Cellular and Molecular Medicine|June 12, 2012
Dopaminergic-like cells from epigenetically reprogrammed mesenchymal stem cellsZhiying Zhang, Arshak R Alexanian
Hematological Oncology|April 1, 1988
Genotypic and phenotypic characteristics of multiple myelomaB Barlogie, J Epstein, R Alexanian
Investigational New Drugs|January 19, 2000
Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist--trihydrochloride of [1,2,5-trimethyl-4-phenyl-4-beta-[N-(beta-ethylamino)-N-4'-methoxybe nzy l]-ethylamino] piperidine (AR-2)A R Alexanian, N S Arutyunian
Seminars in Hematology|August 7, 2001
Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experienceJ Crowley, J Jacobson, R Alexanian
Archives of Pathology & Laboratory Medicine|March 2, 1999
Differential diagnosis of monoclonal gammopathiesR Alexanian, D Weber, F Liu
Clinics in Haematology|February 1, 1982
Interferon treatment for multiple myelomaR Alexanian, J Gutterman, H Levy
American Journal of Hematology|December 1, 1995
Light-heavy chain deposition disease progressing to multiple myelomaD Daliani, D Weber, R Alexanian
American Journal of Clinical Oncology|June 1, 1991
Alpha-interferon combination therapy of resistant myelomaR Alexanian, B Barlogie, J Gutterman
Pageof 20

Showing results (41-50 of 196) with videos related to

Sort By:
Pageof 20
Seminars in Hematology|January 1, 1995
Management of multiple myelomaR Alexanian, M A Dimopoulos
Journal of Tissue Engineering and Regenerative Medicine|June 8, 2012
The neural plasticity of early-passage human bone marrow-derived mesenchymal stem cells and their modulation with chromatin-modifying agentsZhiying Zhang, Arshak R Alexanian
Journal of Cellular and Molecular Medicine|June 12, 2012
Dopaminergic-like cells from epigenetically reprogrammed mesenchymal stem cellsZhiying Zhang, Arshak R Alexanian
Hematological Oncology|April 1, 1988
Genotypic and phenotypic characteristics of multiple myelomaB Barlogie, J Epstein, R Alexanian
Investigational New Drugs|January 19, 2000
Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist--trihydrochloride of [1,2,5-trimethyl-4-phenyl-4-beta-[N-(beta-ethylamino)-N-4'-methoxybe nzy l]-ethylamino] piperidine (AR-2)A R Alexanian, N S Arutyunian
Seminars in Hematology|August 7, 2001
Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experienceJ Crowley, J Jacobson, R Alexanian
Archives of Pathology & Laboratory Medicine|March 2, 1999
Differential diagnosis of monoclonal gammopathiesR Alexanian, D Weber, F Liu
Clinics in Haematology|February 1, 1982
Interferon treatment for multiple myelomaR Alexanian, J Gutterman, H Levy
American Journal of Hematology|December 1, 1995
Light-heavy chain deposition disease progressing to multiple myelomaD Daliani, D Weber, R Alexanian
American Journal of Clinical Oncology|June 1, 1991
Alpha-interferon combination therapy of resistant myelomaR Alexanian, B Barlogie, J Gutterman
Pageof 20